Cocoa and Dark Chocolate Polyphenols: From Biology to Clinical Applications.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing mechanisms and clinical applications without systematic review methodology
PubMed 28649251 · doi:10.3389/fimmu.2017.00677
What was done
This narrative review summarizes the biological pathways and clinical trial literature regarding the consumption of cocoa and dark chocolate polyphenols. It evaluates mechanistic data—including endothelial nitric oxide synthase (eNOS) activation, toll-like receptor 4 (TLR4)/nuclear factor κB (NF-κB)/STAT signaling modulation, and gut microbiota interactions—alongside clinical applications in cardiovascular, neurological, metabolic, and intestinal disorders.
What was found
The abstract reports no quantitative values, sample sizes, or effect estimates. It qualitatively describes that cocoa polyphenols promote vasodilation and cardioprotection via eNOS activation and nitric oxide release, downregulate inflammatory signaling, and shift the gut microbiome toward a tolerogenic profile. It notes that while clinical trial findings are not always concordant across healthy and patient cohorts, biomarker improvements frequently correlate with clinical symptom improvements.
Why it matters
It provides a high-level conceptual map linking the cellular mechanisms of cocoa polyphenols (endothelial function, immune regulation, and microbiome modulation) to potential therapeutic applications in age-related neurovascular and cardiometabolic conditions.
Limits
As a narrative review, it lacks a systematic literature search, standardized study selection criteria, and formal risk-of-bias assessment. The abstract reports no numerical data, effect sizes, or confidence intervals, and explicitly notes discordance among clinical trial results without quantitative reconciliation.
Cited by
- supports Cocoa flavanols increase nitric oxide synthase activity in the endothelium.